Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy

The number of approved or investigational late phase viral vector gene therapies (GTx) has been rapidly growing. The adeno-associated virus vector (AAV) technology continues to be the most used GTx platform of choice. The presence of pre-existing anti-AAV immunity has been firmly established and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorovits, Boris, Azadeh, Mitra, Buchlis, George, Fiscella, Michele, Harrison, Travis, Havert, Mike, Janetzki, Sylvia, Jawa, Vibha, Long, Brian, Mahnke, Yolanda D., McDermott, Andrew, Milton, Mark, Nelson, Robert, Vettermann, Christian, Wu, Bonnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132926/
https://www.ncbi.nlm.nih.gov/pubmed/37101079
http://dx.doi.org/10.1208/s12248-023-00814-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132926/
https://www.ncbi.nlm.nih.gov/pubmed/37101079
http://dx.doi.org/10.1208/s12248-023-00814-5

Ejemplares similares